



Company Overview

JanOne (NASDAQ: JAN) is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery disease ("PAD"), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in early 2021. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions and neuropathic pain. JanOne continues to operate its legacy businesses under their current brand names, which are undergoing review to determine appropriate strategic alternatives.

ALT5 Sigma to Exhibit at iFX EXPO Dubai January 14-16, 2025

Jan 9 2025, 11:30 AM EST

ALT5 Sigma Announces Results of 2024 AGM and Corporate Update

Dec 18 2024, 4:00 PM EST

ALT5 Sigma Reports Fiscal Financial Results for Third Quarter 2024

Nov 12 2024, 4:50 PM EST

Stock Overview

Symbol	ALTS
Exchange	Nasdaq
Market Cap	91.03m
Last Price	\$6.47
52-Week Range	\$0.50 - \$7.09

01/08/2025 09:00 PM EST

Management Team

Peter Tassiopoulos

Chief Executive Officer

Tony Giordano, Ph.D.

Chief Scientific Officer

Virland A. Johnson

Chief Financial Officer

JanOne Inc.

325 E. Warm Springs Road

Suite 102

Las Vegas, NV 89119

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.